Browsing by Author "Cortés-Hernández J."

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    ItemMetadata only
    B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment
    (2025-01-01) Agmon-Levin N.; Ignatenko S.; Gordienko A.; Cortés-Hernández J.; Narongroeknawin P.; Romanowska-Próchnicka K.; Shen N.; Ciferská H.; Kodera M.; Cheng-Chung W.J.; Leszczynski P.; Lan J.L.; Mysler E.; Wojciechowski R.; Tarr T.; Vishneva E.; Chen Y.H.; Kaneko Y.; Finzel S.; Hoi A.; Okada M.; Koolvisoot A.; Lee S.S.; Lie D.; Kaneko H.; Rojkovich B.; Sun L.; Zotkin E.; Viallard J.F.; López B.P.M.; Ghanshani S.A.; Lau C.; Avrameas A.; Sips C.; Oliver S.J.; Agmon-Levin N.; Mahidol University
    Objectives: B cell depletion or B cell activating factor (BAFF) blockade has shown benefits in systemic lupus erythematosus (SLE). We compared ianalumab, a monoclonal antibody targeting BAFF receptor (BAFF-R)-expressing B cells to lyse B cells and block BAFF-R, with placebo for SLE treatment combined with standard therapies. Methods: Patients with active SLE were randomised (1:1) to monthly subcutaneous ianalumab 300 mg or placebo. The primary outcome was a composite of SLE Responder Index (SRI)-4 at week 28 in patients successfully achieving corticosteroid (CS) tapering criteria. Patients subsequently received open-label (OL) ianalumab until week 48, followed by exploratory assessments at week 52 and off-treatment to week 68. Safety monitoring continued until B cell recovery. This report describes interim analyses conducted on the week 68 dataset. Results: Sixty-seven patients were randomised and received blinded treatments until week 28. The primary composite endpoint was more frequently achieved with ianalumab vs placebo: 15/34 (44.1%) vs 3/33 (9.1%), with responses sustained to week 52 and replicated by placebo transitioned to OL ianalumab: 15/33 (45.5%) and 13/32 (40.6%). Positive treatment effects were consistently observed across other lupus disease activity outcomes (SRI-6, Definition of Remission in SLE, Lupus Low Disease Activity State, flare reduction, and CS use) at week 28, with clinical benefits until weeks 52 and 68. Ianalumab was not associated with increased serious adverse events or serious infections. Nonserious local injection site reactions occurred more frequently with ianalumab. Conclusions: At week 28, reduced disease activity was observed in patients with SLE receiving ianalumab plus standard therapies compared with those receiving standard therapies alone, with sustained benefits with further treatment until 1 year, which was well tolerated.